Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05041322 · ClinicalTrials.gov registry record · Phase 2

Improving Ventilatory Capacity in Those With Chronic High Level SCI

A Phase 2 study of Spinal Cord Injuries, sponsored by Spaulding Rehabilitation Hospital.

Completed
Registry status
Phase 2
Development phase
13
Enrollment target
1
Study location

NCT05041322 is a Phase 2 study of Spinal Cord Injuries that has completed, run by Spaulding Rehabilitation Hospital. The registered enrollment target is 13 participants, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05041322, a Phase 2 study of Spinal Cord Injuries, has completed, sponsored by Spaulding Rehabilitation Hospital.

COMPLETED
Registry status
Phase 2
Development phase
13 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out if taking the drug Buspar will increase breathing capacity in individuals with spinal cord injuries.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Buspirone

Study Locations (1)

Massachusetts

  • Spaulding Hospital Cambridge - Cambridge

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2020-11-29
Est. Completion 2024-11-01
Phase Phase 2

Sponsor

Spaulding Rehabilitation Hospital

101 total trials

What the Registry Record Tells You About NCT05041322

The ClinicalTrials.gov registry entry for NCT05041322 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target (79% lower). The listed sponsor is Spaulding Rehabilitation Hospital, which has 101 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Spinal Cord Injuries appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05041322 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05041322 about?

NCT05041322 is a clinical study titled "Improving Ventilatory Capacity in Those With Chronic High Level SCI". The purpose of this study is to find out if taking the drug Buspar will increase breathing capacity in individuals with spinal cord injuries.

What is the current status of trial NCT05041322?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2020-11-29. Estimated completion is 2024-11-01.

What conditions does trial NCT05041322 study?

This clinical trial studies the following conditions: Spinal Cord Injuries.

What interventions are being tested in trial NCT05041322?

The interventions under investigation include: Placebo (DRUG), Buspirone (DRUG).

Who is sponsoring clinical trial NCT05041322?

This trial is sponsored by Spaulding Rehabilitation Hospital, which has 101 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05041322 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.